Tigecycline: A critical analysis

Clinical Infectious Diseases

Volumn 43, Issue 4, 2006, Pages 518-524

  Stein, Gary E ^a,d   Craig, William A ^b,c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b University of Wisconsin Health   (United States)

^c WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CILASTATIN PLUS IMIPENEM; CYTOCHROME P450; GLYCYLGLYCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL INFECTION; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL GROWTH; BILIARY EXCRETION; CLINICAL TRIAL; DIARRHEA; DISTRIBUTION VOLUME; DRUG APPROVAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; ESCHERICHIA COLI; FOOD AND DRUG ADMINISTRATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEARING LOSS; HEPATITIS; HUMAN; HYPERPIGMENTATION; KIDNEY FUNCTION; KLEBSIELLA PNEUMONIAE; LUPUS LIKE SYNDROME; MACULOPAPULAR RASH; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM; NAUSEA; NONHUMAN; PANCREATITIS; PRIORITY JOURNAL; PRURITUS; REVIEW; SKIN INFECTION; URTICARIA; VANCOMYCIN RESISTANT ENTEROCOCCUS; VERTIGO; VOMITING;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

EID: 33746616007     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/505494     Document Type: Review

References (29)

1. Petersen PJ, Jacobus NV, Weiss WJ, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43:738-44.
2. Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005; 41(Suppl 5):S303-14.
3. Bradford PA, Petersen PJ, Young M, et al. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob Agents Chemother 2005; 49:3903-9.
4. Fritsche TR, Strabala PA, Sader HS, Dowzicky MJ, Jones RN. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. Diagn Microbiol Infect Dis 2005; 52:209-13.
5. Ruzin A, Keeney D, Bradford PA. AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. Antimicrob Agents Chemother 2005; 49:791-3.
6. Visalli MA, Murphy E, Projan SJ, Bradford PA. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother 2003; 47:665-9.
7. Milatovic D, Schmitz F-J, Verhoef J, Fluit AC. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003; 47:400-4.
8. Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis 2005; 52:181-6.
9. Bradford PA, Weaver-Sands T, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005; 41 (Suppl 5):S315-32.
10. Muralidharan G, Micalizzi M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49:220-9.
11. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005; 41(Suppl 5):S333-40.
12. Muralidharan G, Cruncillo RJ, Micalizzi M, et al. Effects of age and sex in single-dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob Agents Chemother 2005; 49:1656-9.
13. Conte JE Jr, Golden JA, Kelly MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005; 25:523-9.
14. Sun HK, Ong CT, Umer A, et al. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 2005; 49:1629-32.
15. van Ogtrop ML, Andes D, Stamstad TJ, et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,228) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2000; 44:943-9.
16. Meagher A, Passarell J, Cirincione B, et al. Exposure-response analysis of the efficacy of tigecycline in patients with complicated skin and skin-structure infections [abstract P1184]. Clin Microbiol Infect 2005; 11(Suppl 2).
17. Passarell JA, Liolios K, Meagher AK, et al. Exposure-response analysis of the efficacy of tigecycline (T) in patients with complicated intraabdominal infections (cIAI) [abstract A-1155], In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: Americian Society for Microbiology, 2005:22.
18. Lefort A, Lafaurie M, Massias L, et al. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2003; 47:216-22.
19. Edelstein PH, Weiss WJ, Edelstein MAC. Activites of tigecycline (GAR-936) against Legionella pneumophila and in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 2003; 47:533-40.
20. Fang GD, Weiss WJ, Scheid WM. Comparative efficacy of GAR-936, a novel glycylcycline, alone and in combination with vancomycin against highly penicillin-resistant Streptococcus pneumoniae (PRSP) experimental meningitis in rabbits [abstract B-868]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2000:51.
21. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41:S341-53.
22. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. The efficacy and safety of tigecycline for the treatment of complicated intraabdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41:S354-66.
23. Livermore DM. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother 2005; 56:611-4.
24. Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004; 26:704-14.
25. Stein GE. Safety of newer parenteral antibiotics. Clin Infect Dis 2005; 41(Suppl 5):S293-302.
26. Tigecycline (Tygacil). Med Lett Drugs Ther 2005; 47:73-4.
27. Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 2005; 56:20-51.
28. Paterson DL. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004; 38(Suppl 4):S341-5.
29. DiNubile MJ, Chow JW, Satishchaudran V, et al. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intra-abdominal infections. Antimicrob Agents Chemother 2005; 49:3217-21.